Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors are the latest addition to the class of oral glucose‐lowering drugs. They have been rapidly adopted into clinical practice because of therapeutic advantages, including weight loss and reduction in blood pressure, in addition to glycaemic benefits and a low intrinsic risk of hypoglycaemia. Although there are extensive data on the clinical effects of SGLT2 inhibition, the metabolic effects of inhibiting renal glucose reabsorption have not been fully described. Recent studies have identified compensatory metabolic effects, such as an increase in endogenous glucose production, and have also shown an increase in glucagon secretion during SGLT2 inhibition. In addition, there is a discrepancy between the expected and observed weight loss found in clinical studies on SGLT2 inhibitors, probably as a result of changes in energy balance with this treatment approach. SGLT2 inhibition is likely to have intriguing effects on whole body metabolism which have not been fully elucidated, and which, if explained, might help optimize the use of this new class of medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 2×
“The body maintains this equilibrium through a complex process of metabolic adaptation, substrate utilisation (for example, the competitive process between carbohydrate and fat in the glucose–fatty acid cycle [42]) and compensatory responses, especially when it comes to energy loss.”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Quantification of the effect of energy imbalance on bodyweight
Hall, K. D., Sacks, G., Chandramohan, D., Chow, C. C., Wang, Y. C., Gortmaker, S. L., & Swinburn, B. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60812-x · Cited by 1,165
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“A significant undesirable side effect of some agents, however, is weight gain, and drugs that cause weight loss are preferable to physicians and patients, especially given the evidence that lifestyle intervention [5] or metabolic surgery can improve glycaemic control or even induce T2DM remission.”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 10×
“SGLT2 inhibition while having a stimulatory effect on glucagon [7,8,80], decreases insulin concentration [8], thus increasing the glucagon to insulin ratio.”
BackgroundInfluentialBolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 5×
“This suggests that weight loss secondary to SGLT2 inhibition is mainly because of reduced fat mass [45,50], secondary to fatty acid oxidation.”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity
Parton, L. E., Ye, C. P., Coppari, R., Enriori, P. J., Choi, B., Zhang, C.-Y., Xu, C., Vianna, C. R., Balthasar, N., Lee, C. E., et al. (2007) · Nature · doi:10.1038/nature06098 · Cited by 700 · cited 1×
“Nevertheless, this mechanism is possibly impaired in obesity, as shown in animal models [56] and hence makes it a less likely explanation in the typical patient with T2DM taking SGLT2 inhibitors; however, the possibility of SGLT2 expression in the brain cannot be discarded [57]; in the light of SGLT2 expression in pan…”
Background
Cited by
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“SGLT2i do not have effect on resting or postprandial energy expenditure, hence, the difference between expected weight loss and observed weight loss implies gradual compensatory increase in caloric intake [76,77].”
BackgroundInfluentialTsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
“SGLT-2 inhibitors cause glycosuria and osmotic diuresis, which translate to calorific loss and reductions in blood pressure, respectively.(13) However, for many antidiabetic drugs there is a paucity of head-to-head trials.”
BackgroundLiu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
“Compensatory metabolic adaptations may account for the difference, although this remains to be confirmed.(65) Reports of euglycaemic diabetes ketoacidosis in insulin-treated T2D patients receiving SGLT-2 inhibitors have emerged,(65,108) resulting in warnings being issued by the US Food and Drug Administration and the…”
BackgroundSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
“However, in some recent experiments, these results have not been confirmed, and a slight reduction in both triglycerides and LDL cholesterol has been highlighted [259].”
ResultVerhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
“SGLT2i inhibits renal glucose reabsorption, promoting approximately 75 g of urinary glucose excretion with an associated caloric loss of approximately 300 kcal/day [13].”
Background
Metadata
- Authors
- Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-12-10
- Volume
- 18
- Issue
- 2
- Pages
- 125-134
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1898894592
- Cited by
- 116
- References
- 23
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.